Update

 

TIDMMDX 
 
RNS Number : 5798M 
Meldex International PLC 
30 January 2009 
 

+--------------------------------------+--------------------------------------+ 
| For Immediate Release                |                      30 January 2009 | 
+--------------------------------------+--------------------------------------+ 
 
 
 
 
Meldex International Plc ("Meldex " or "the Company") 
 
 
Update to Review of Business Activities 
 
 
Cambridge, UK, 30 January, 2009: Meldex International Plc (AIM: MDX), the 
directors report further progress with their review of the Company's business 
activities. 
 
 
Dexo LLC 
The Company's subsidiary Dexo LLC, based in Kansas, USA, has ceased trading. 
Sales revenues generated by Dexo LLC have been negligible, therefore the Company 
does not expect the closure to have any material impact on sales revenues going 
forward and the cost savings will help reduce the Company's fixed cost base. 
However, this closure will give rise to an impairment on the balance sheet. 
 
 
Development Programmes 
In addition to the development programmes named on 23 January 2009, the Company 
is currently engaged in the following programmes: 
 
 
  *  Advanced Solupol(TM) for gastric reflux; and, a contract with a subsidiary of 
  Merck Serono for development of product employing one of the Company's enabling 
  systems. 
 
 
 
  *  All development programmes, other than those announced on 23 January are 
  currently under review and their status will be advised as and when determined, 
  and a further update will be provided on or before 6 February 2009. 
 
 
 
Clarification regarding Rocgel 
The Company no longer has any interest in the Rocgel product, its trademark or 
its marketing authority. The product in development previously announced as 
Rocgel Advanced is being developed under the Solupol(TM) brand referred to 
above. 
 
 
 
 
For information contact: 
 
Gary Cressman [phone] 
Meldex International plc 
 
 
Barry Muncaster+44 (0) 1223 394 250 
Meldex International plc 
[e-mail] 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCBLGDBGXXGGCG